Organization
Meridian Bioscience
7 clinical trials
Clinical trial
Companion Protocol for the ¹³C-Methacetin Breath Test Using the BreathID® MCS System for Conatus Phase 2 Study of Emricasan, an Oral Caspase Inhibitor, Under Protocol IDN-6556-17Status: Terminated, Estimated PCD: 2019-07-15
Clinical trial
The Effect of High Dose Citric on PPI (Proton Pump Inhibitors)Induced False Negative H. Pylori UBT RatesStatus: Completed, Estimated PCD: 2009-11-01
Clinical trial
Clinical Confirmation Study to Confirm Safety and Presence of H. Pylori With 13C-Urea Breath Test Using the BreathID® Hp and BreathID® Hp Lab Systems in the Pediatric PopulationStatus: Completed, Estimated PCD: 2017-10-30
Clinical trial
Evaluation of the Capability of the ¹³C-Octanoate Breath Test (OBT) Measurement in Patients With Chronic Liver Disease to Differentiate Between Presence and Absence of HCC Determined by MRIStatus: Terminated, Estimated PCD: 2012-05-01
Clinical trial
Companion Protocol for the ¹³C-Methacetin Breath Test Using the BreathID® MCS System for Conatus Phase 2 Study of Emricasan, an Oral Caspase Inhibitor, Under Protocol IDN-6556-14 (NCT02960204)Status: Completed, Estimated PCD: 2019-04-08
Clinical trial
Companion Protocol for the ¹³C-Methacetin Breath Test (MBT) for Use in Bristol-Myers Squibb Phase 2b Studies for BMS-986036 (PEG-FGF21), Under Studies Referenced in NCT03486899, NCT03486912Status: Completed, Estimated PCD: 2020-08-18